<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Ardea Biosciences Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/ardea-biosciences-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(RDEA) Ardea Biosciences &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/07/15/rdea-ardea-biosciences-bull-of-the-day/79145</link>
		<comments>http://www.stockbloghub.com/2011/07/15/rdea-ardea-biosciences-bull-of-the-day/79145#comments</comments>
		<pubDate>Fri, 15 Jul 2011 14:09:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences Inc.]]></category>
		<category><![CDATA[RDEA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79145</guid>
		<description><![CDATA[We are upgrading Ardea Biosciences Inc (RDEA) to Outperform from Neutral due to the promise shown by its lead pipeline candidate lesinurad, which is being developed for treating hyperuricemia and gout. Lesinurad, which has performed well in clinical studies, will target a market with huge unmet need on approval. The current therapies have limited efficacy with many gout patients failing to respond favorably to these therapies. This should provide lesinurad with the opportunity to take away share from currently approved therapies. The impressive balance sheet at Ardea, which has been strengthened by the signing of the lucrative agreement with Bayer, is another positive for the company. We believe that the current price represents an attractive entry point for long-term investors. ARDEA BIOSCIENC (RDEA): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/15/rdea-ardea-biosciences-bull-of-the-day/79145/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SVNT) Savient Pharmaceuticals Gout Drug Trials Suspended</title>
		<link>http://www.stockbloghub.com/2009/09/18/rdea-savient-pharmaceuticals-gout-drug-trials-suspended/15566</link>
		<comments>http://www.stockbloghub.com/2009/09/18/rdea-savient-pharmaceuticals-gout-drug-trials-suspended/15566#comments</comments>
		<pubDate>Fri, 18 Sep 2009 17:14:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences Inc.]]></category>
		<category><![CDATA[RDEA]]></category>
		<category><![CDATA[Savient Pharmaceuticals Inc]]></category>
		<category><![CDATA[SVNT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15566</guid>
		<description><![CDATA[Savient Pharmaceuticals Inc. (SVNT), after meeting officials from the U.S. Food and Drug Administration (FDA) on Monday, announced that the agency does not expect further clinical trials to be conducted for its gout drug Krystexxa, as the company has now reverted to its original manufacturing process for producing phase III trial material for Krystexxa. The meeting discussed the Complete Response Letter (CRL) received on July 31, 2009 from the FDA, whereby the agency refused to approve the Biologics License Application (BLA) for Krystexxa (pegloticase) because Savient changed the way the drug was manufactured, among other issues. As a result of this ruling, Savient stated that it can meet its previously announced timeline of filing the resubmission in response to the CRL in early 2010 .The resubmission will be classified as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/rdea-savient-pharmaceuticals-gout-drug-trials-suspended/15566/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

